Serum fibroblast growth factor 21 levels in polycystic ovary syndrome

References

• Stein I, Leventhal M. Amenorrhoea associated with polycystic ovaries. Am J Obstet Gynecol 1935;29:181–185.
   Google Scholar
• Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27:877–902.
   PubMed Web of Science ®Google Scholar
• Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Metab 2005;90:4650–4658.
   PubMed Web of Science ®Google Scholar
• Bernasconi D, Del Monte P, Meozzi M, Randazzo M, Marugo A, Badaracco B, Marugo M. The impact of obesity on hormonal parameters in hirsute women. Metabolism 1996;45:72–75.
   PubMed Web of Science ®Google Scholar
• Bjorntop P. Abdominal obesity and the metabolic syndrome. Ann Med 1992;24:465–468.
   PubMed Web of Science ®Google Scholar
• McKeehan WL WF, Kan M. The heparan sulphate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998;59:135–176.
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rustani M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159–178.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2: REVIEWS3005.
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM: Evolution of the FGF and FGFR gene families. Trends Genet 2004;20:563–569.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, et al FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627–1635.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000;1492:203–206.
   PubMed Web of Science ®Google Scholar
• Dostálová I, Haluzíková D, Haluzík M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res 2009;58:1–7. Review.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, Asada M, Komi-Kuramochi A, Oka S, Imamura T. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008;22:1006–1014.
   PubMed Web of Science ®Google Scholar
• Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282:26687–26695.
   PubMed Web of Science ®Google Scholar
• Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006;5:2470–2478.
   Google Scholar
• Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018–6027.
   PubMed Web of Science ®Google Scholar
• Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, et al Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58:250–259.
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos D, Almeda-Valdes P, Aguilar-Salinas CA, Cuevas-Ramos G, Cuevas-Sosa AA, Gomez-Perez FJ. The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. Curr Diabetes Rev 2009;5:216–220.
   PubMedGoogle Scholar
• Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP, Wong KK. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 2008;74:403–412.
   PubMed Web of Science ®Google Scholar
• Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A, Kharitonenkov A. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 2007;210:1–6.
   PubMed Web of Science ®Google Scholar
• Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002;18 Suppl 2:S5–S9. Review.
   PubMedGoogle Scholar
• Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M. FGF21 attenuates lipolysis in human adipocytes – a possible link to improved insulin sensitivity. FEBS Lett 2008;582:1725–1730.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM- Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
   Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Polycystic ovary syndrome: arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897–1899.
   PubMed Web of Science ®Google Scholar
• Mikael Ryden. Fibroblast growth factor: an overview from a clinical perspective. Cell Mol Life Sci 2009;66:2067–2073.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, et al Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246–1253.
   PubMed Web of Science ®Google Scholar
• Dostálová I, Kaválková P, Haluzíková D, Lacinová Z, Mráz M, Papezová H, Haluzík M. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008;93:3627–3632.
   PubMed Web of Science ®Google Scholar
• Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8:169–174.
   PubMed Web of Science ®Google Scholar
• Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008;28:188–200.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor 21. Endocrinology 2007;148:774–781.
   PubMed Web of Science ®Google Scholar
• Li L, Yang G, Ning H, Yang M, Liu H, Chen W. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract 2008;82:209–213.
   PubMed Web of Science ®Google Scholar
• Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116:65–68.
   PubMed Web of Science ®Google Scholar
• Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, Meinus S, Reinecke F, Möhlig M, Weickert MO, et al Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009;58:1532–1538.
   PubMed Web of Science ®Google Scholar